10x Genomics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TXG research report →
Range $61 – $110
Price Chart
About the company
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company.
- CEO
- Serge Saxonov
- IPO
- 2019
- Employees
- 1,178
- HQ
- Pleasanton, CA, US
Get TickerSpark's AI analysis on TXG
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.29B
- P/E
- -101.38
- Fwd P/E
- 169.84
- PEG
- 0.22
- P/S
- 10.35
- P/B
- 8.23
- EV/EBITDA
- 133.33
- Div Yield
- 0.00%
- Gross Margin
- 71.88%
- Op Margin
- -11.67%
- Net Margin
- -10.84%
- ROE
- -8.19%
- ROIC
- -7.72%
Latest fiscal year · YoY change
- Revenue
- $642.82M+5.2%
- Gross Profit
- $443.88M+7.1%
- Op Income
- $-110,885,000
- Net Income
- $-43,544,000+76.2%
- EPS
- $-0.35+77.0%
- OCF Growth
- +1941.6%
- FCF Growth
- +2371.2%
- 52W High
- $102.81
- 52W Low
- $15.18
- 50D MA
- $73.20
- 200D MA
- $43.32
- Beta
- 2.03
- RSI (14)
- 36
- Avg Volume
- 3.36M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
10x Genomics posted modest Q3 revenue growth, strong gross margin expansion, and raised full-year guidance as Atera shipments began and demand momentum remained strong in spatial and single cell.· November 5, 2026
- Q3 revenue was $150.7 million, up 1% year over year, with consumables growth offset by a sharp decline in instrument revenue.
- Gross margin improved to 75% from 67% a year ago, helped by lower inventory write-downs and product mix.
- The company started commercial Atera shipments in late September and expects about 50 units shipped by year-end, up from a prior estimate of about 40.
- Full-year 2026 revenue guidance was raised to $625 million-$635 million from $610 million-$630 million.
- Management said demand is not the bottleneck for Atera; production, installation, and customer success are the main constraints.
Revenue in the third quarter was $150.7 million, up 1% year over year. Total consumables revenue increased 5%, with Single Cell consumables up 1% and Spatial consumables up 16%, while total instrument revenue fell 43% as Chromium instruments declined 23% and Spatial instruments declined 57%. Gross margin was 75%, versus 67% in the prior-year period, and operating expenses were $129 million versus $132.5 million a year ago. The company ended the quarter with $576 million in cash, cash equivalents and marketable securities, up $94 million year over year and up $24 million sequentially. For 2026, management raised revenue guidance to $625 million-$635 million, which they said implies 4% to 6% growth excluding nonrecurring patent litigation settlement revenue in 2026 and 2025; they also now expect to ship approximately 50 Atera instruments by year-end, versus about 40 previously. Gross margins are expected to step down sequentially in Q4 and be in the low to mid-60s, with a larger Atera-heavy mix likely keeping 2027 margins below 2026 levels at least initially.
Serge Saxonov framed the quarter as early proof that 10x is positioned for an AI-driven biology cycle, emphasizing that the key bottleneck is generating large, high-resolution biological data. He said Atera is seeing extraordinary customer demand across academia, biopharma, and techbio, with nearly all of the top 20 biopharma companies now having purchased Atera systems or services through Catalyst. His tone was highly optimistic and strategic, focusing on Atera, multimodal single cell, and Sentira as platforms that expand the company’s role in data generation and analysis.
Adam Taich highlighted the hard financials: revenue of $150.7 million, gross margin of 75%, operating expenses of $129 million, and quarter-end cash and marketable securities of $576 million. He attributed the gross margin improvement to lower inventory write-downs and product mix, and noted that instrument revenue declined because fewer units were sold. On outlook, he raised full-year revenue guidance to $625 million-$635 million, said Atera shipment expectations increased to about 50 units by year-end, and warned that gross margins should move down sequentially in Q4 into the low to mid-60s as Atera ramps.
Analysts pressed on the pace of consumables growth, Atera placements, backlog, margin recovery, and the split between customers buying Atera systems versus using Catalyst Research Services. Management said there are lots of orders, but the binding constraints are manufacturing scale-up, installation, and customer training rather than demand. They also said whole transcriptome is the dominant Atera workflow so far, Atera demand is broad across customer types but relatively stronger in biopharma, and Sentira is intended first to reduce analysis bottlenecks and later could support software revenue.
The bull case from this call is that Atera demand appears strong and broad-based very early in the launch, with management repeatedly saying demand is not the constraint. Spatial consumables were better than expected, Xenium remained strong, and management raised full-year revenue guidance while pointing to continued Atera and consumables momentum into Q4 and 2027.
The main risks discussed were execution and ramp constraints: Atera shipments are still early, production and installation are the limiting factors, and gross margins are expected to fall sequentially in Q4 and likely remain under pressure as the instrument-heavy Atera rollout continues. Instrument revenue was still down sharply year over year, and management acknowledged that the Apex transition lowers per-reaction pricing, which can pressure top-line growth even as usage rises.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 96.6%
- Shares Outstanding
- 121.45M
- Float Shares
- 117.35M
of shares held by institutions
405 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 18.14M | ▲ 509.43K |
| Vanguard Group Inc | 13.02M | ▼ 256.42K |
| Blackrock, Inc. | 11.57M | ▲ 770.38K |
| Ark Investment Management LLC | 6.27M | ▼ 3.73M |
| Vanguard Portfolio Management LLC | 5.91M | ▼ 1.07M |
| Vanguard Capital Management LLC | 5.39M | ▲ 311.10K |
| Price T Rowe Associates Inc | 4.54M | ▲ 4.38M |
| Quantinno Capital Management LP | 3.69M | ▼ 1.78M |
| Morgan Stanley | 3.27M | ▼ 80.08K |
| Goldman Sachs Group Inc | 3.15M | ▼ 822.94K |
| Geode Capital Management, LLC | 3.13M | ▲ 51.66K |
| Jpmorgan Chase & Co | 2.85M | ▲ 2.10M |
Held by 502 ETFs
Biggest fund positions in TXG by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 10, 26 | Saxonov Serge | sell | 31,000 |
| Oct 28, 26 | Satpathy Ansuman | other | 0 |
| Oct 28, 26 | Gilliam Joseph E | other | 0 |
| Sep 22, 26 | SULIMAN SHEHNAAZ | sell | 292 |
| Sep 22, 26 | SULIMAN SHEHNAAZ | sell | 614 |
| Sep 22, 26 | SULIMAN SHEHNAAZ | sell | 1,325 |
| Sep 22, 26 | SULIMAN SHEHNAAZ | sell | 2,270 |
| Sep 22, 26 | SULIMAN SHEHNAAZ | sell | 1,222 |
| Sep 22, 26 | Saxonov Serge | sell | 1,000 |
| Sep 22, 26 | Saxonov Serge | sell | 2,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TXG coverage
Recent articles, reports, and earnings notes.
No research on TXG yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TXG report →10x Genomics Expands Global Research in Blood-Based Diagnostics for Autoimmune Disease with Two New Collaborations
prnewswire.com · Nov 16
10x Genomics' Xenium Platform to Support Breast Cancer Biomarker Study
zacks.com · Nov 12
Shanghai Precision Diagnostics and Fudan University Shanghai Cancer Center Launch Breast Cancer Biomarker Study Using 10x Genomics' Xenium Platform
prnewswire.com · Nov 10
What Torex Gold Resources (TXG) Said on Its Q3 Earnings Call
marketbeat.com · Nov 8
10x Genomics $TXG Stock: Chicago Partners Investment Group LLC Lowers Position
defenseworld.net · Nov 8
10x Genomics Launches Sentira AI Tool to Simplify Cell Analysis
zacks.com · Nov 6
TXG Q3 Earnings Call Highlights Atera Launch and Raised Outlook
zacks.com · Nov 6
What 10x Genomics (TXG) Said on Its Q3 Earnings Call
marketbeat.com · Nov 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.